Abstracts tagged "Biologics"

Abstract Number: 2406 • 2014 ACR/ARHP Annual Meeting
Primary Non-Adherence, Associated Clinical Outcomes and Healthcare Resource Utilization Among Rheumatoid Arthritis Patients Prescribed Injectable Biologics
J. Harnett¹, D. Wiederkehr¹, R. Gerber², D. Gruben², J. Bourret³ and A. Koenig³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Injectable biologics are commonly used to treat patients (pts) with moderate to severe rheumatoid arthritis (RA); the frequency with which they are prescribed but…
Abstract Number: 1538 • 2014 ACR/ARHP Annual Meeting
Sustained Clinical Benefit with Multiple Courses of Rituximab in Second LineÂ forÂ All Rheumatoid Arthtritis PatientsÂ Irrespective to the Inhibitor of Tumour Necrosis FactorÂ Previously Used
Ioan Ancuta¹, Ruxandra Ionescu², Catalin Codreanu³, Andra Balanescu², Elena Rezus⁴, Maria Suta⁵, Paulina Ciurea⁶, Mihaela Milicescu⁷, Dan Nemes⁸, Codrina Ancuta⁹, Mihai Bojinca¹⁰, Magda Parvu¹¹ and Horatiu Popoviciu¹², ¹“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ³5 Thomas Masaryk Street, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ⁴Rheumatology, Recovering Clinical Hospital, Iasi, Romania, ⁵317 Tomis Str. , Bl. 4A, ap. 3, Constanta Municipal Hospital, Constanta, Romania, ⁶Clinical County Hospital,Craiova, Craiova, Romania, ⁷Rheumatology, "Dr. I. Cantacuzino" Clinical Hospital, Bucharest, Romania, ⁸Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, ⁹G.T.Popa Center for Biomedical Research, Iasi, Romania, ¹⁰Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ¹¹Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania, ¹²Rheumatology, University of Medicine and Pharmacy Targu Mures, Tg Mures, Romania
Background/Purpose: In the last decade, biologic therapy changed dramatically treatment options for rheumatoid arthritis (RA). However, a significant number of patients failed to maintain the…
Abstract Number: 907 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Tenosynovitis Score Is Responsive to Biologic Treatment in Patients with Rheumatoid Arthritis
Hilde B. Hammer¹ and Tore K. Kvien², ¹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

Background/Purpose: Ultrasound (US) is sensitive for detecting tenosynovitis in patients with rheumatoid arthritis (RA), where the synovitis can be assessed by grey scale (GS) and…
Abstract Number: 2408 • 2014 ACR/ARHP Annual Meeting
Frequency of Rheumatoid Arthritis Flares in Clinical Practice: Analysis of a Monocentric Cohort of Patients in Stable Remission or Low Disease Activity
Francesca Ometto¹, Costantino Botsios², Livio Bernardi¹, Bernd Raffeiner^2,3, Leonardo Punzi⁴ and Andrea Doria⁴, ¹Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ³Department of Medicine, Rheumatology - General Hospital Bolzano, Bolzano, Italy, ⁴Department of Medicine - DIMED, University of Padova, Padova, Italy
Background/Purpose Rheumatoid arthritis (RA) flares are predictive of structural damage even in case of stable disease course. No definition for flare has been validated to…
Abstract Number: 1511 • 2014 ACR/ARHP Annual Meeting
COVA322: A Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Wibke Lembke, Bernd Schlereth, Julian Bertschinger, Dragan Grabulovski and Mathias Locher, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologic therapeutics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there is still…
Abstract Number: 853 • 2014 ACR/ARHP Annual Meeting
Cancer Incidence in TNF Inhibitor Treated Patients with Axial Spondyloarthritis and Psoriatic Arthritis – a Study from the ARTIS and Danbio Registers
Johan Askling¹, Lene Dreyer², Merete Lund Hetland³, Lennart Jacobsson⁴, Lars-Erik Kristensen⁵, Bente Glintborg⁶, . ARTIS and DANBIO study groups⁷ and Karin Hellgren⁸, ¹Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ²Gentofte University Hospital, Hellreup, Denmark, ³Glostrup University Hospital, Glostrup, Denmark, ⁴Sahlgrenska Academy, Gothenburg, Sweden, ⁵Lund University, Lund, Sweden, ⁶Gentofte University Hospital, Gentofte, Denmark, ⁷Karolinska Institutet, stockholm, Sweden, ⁸Karolinska Institutet, Stockholm, Sweden
Background/Purpose Most studies of the safety profile of TNF inhibitors (TNFi) - in particular in relation to cancer risks - have been performed in patients…
Abstract Number: 2375 • 2014 ACR/ARHP Annual Meeting
Should Physician Reduce patients’ Glucocorticoids to Offset the Risk of Serious Infection Event Among RA Patients Who Switched from Non-Biologic Dmards and Glucocorticoid to Biologics?
Huifeng Yun¹, Lang Chen², George W. Reed³, Joel M. Kremer⁴, Jeffrey D. Greenberg⁵ and Jeffrey R. Curtis⁶, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Corrona, LLC., Southborough, MA, ⁴Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁵Rheumatology, New York University School of Medicine, New York, NY, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Glucocorticoids (GCs) and biologic disease-modifying antirheumatic drugs (DMARDs) have previously been associated with serious infection events (SIEs) among rheumatoid arthritis (RA) patients. For patients…
Abstract Number: 1505 • 2014 ACR/ARHP Annual Meeting
The Biosimilar Landscape: A Systematic Review of Its Current Status
Niti Goel^1,2 and Kamali Chance³, ¹Rheumatology Center of Excellence, Quintiles, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Global Biosimilars Unit, Quintiles, Durham, NC
Background/Purpose In the last 5 years, the number of biosimilars in development for the treatment of immunologic diseases has increased as innovator etanercept (ETA), infliximab (IFX), adalimumab…
Abstract Number: 821 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: An Update
Christina D Chambers^1,2, Diana L Johnson¹, Yunjun Luo¹, Ronghui Xu^2,3 and Kenneth L Jones¹, ¹University of California San Diego Department of Pediatrics, La Jolla, CA, ²University of California San Diego Department of Family and Preventive Medicine, La Jolla, CA, ³University of California San Diego Department of Mathematics, La Jolla, CA
Background/Purpose Adalimumab is a fully human monoclonal antibody to tumor necrosis factor alpha and is approved for several indications including rheumatoid arthritis (RA). Methods The…
Abstract Number: 2120 • 2014 ACR/ARHP Annual Meeting
Societal Preferences for Rheumatoid Arthritis Treatments. Evidence from a Discrete Choice Experiment
Mark Harrison^1,2, Carlo Marra³, Kam Shojania⁴ and Nick Bansback⁵, ¹University of Manchester, Manchester, United Kingdom, ²University of British Columbia, Vancouver, BC, Canada, ³Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁴Medicine, University of British Columbia, Vancouver, BC, Canada, ⁵School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose The cost-effectiveness of new interventions is increasingly assessed using the cost per quality-adjusted life year (QALY). QALYs are calculated by multiplying the length of…
Abstract Number: 1491 • 2014 ACR/ARHP Annual Meeting
Discovery and Characterization of COVA322, a Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Dragan Grabulovski, Michela Silacci, Wibke Lembke, Wenjuan Zha, Richard Woods, Roger Santimaria, Julian Bertschinger and Mathias Locher, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, recent data suggest that…
Abstract Number: 581 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Etanercept in Axial Spondyloarthritis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Maxime Dougados¹, Emily Wood², Bernard Combe³, Corinne Miceli-Richard⁴, Francis Berenbaum⁵, Nandan Koppiker⁶, Arnaud Dubanchet⁷ and Isabelle Logeart⁷, ¹Université Paris René Descartes and Hôpital Cochin, Paris, France, ²Biostatistics, Quanticate, Hitchin, England, ³Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁴Rheumatology Department, Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, ⁵Service de Rhumatologie, Saint-Antoine Hospital, Paris, France, ⁶Pfizer PGRD, Sandwich, United Kingdom, ⁷Pfizer, Paris, France
Background/Purpose Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line pharmacotherapy in axial spondyloarthritis (axSpA) but are recommended for use at the lowest effective dose for the shortest…
Abstract Number: 2031 • 2013 ACR/ARHP Annual Meeting
GRAID – Interim Analysis Of The Retrospective German Register In Autoimmune Diseases
Thomas Dörner¹, Enno Schmidt², Christoph Fiehn³, Frank Behrens⁴, Rebecca Fischer-Betz⁵, Martin Fleck⁶, Julia Holle⁷, Joerg C. Henes⁸, Annett M. Jacobi⁹, Christian Kneitz¹⁰, Esther Wittenborn¹¹, Fabian Proft¹², Hendrik Schulze-Koops¹³ and Christof Iking-Konert¹⁴, ¹CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ²Department of Dermatology, University of Lübeck, Lübeck, Germany, ³ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ⁴CIRI/Div. Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, ⁵Department of Rheumatology, University of Düsseldorf, Düsseldorf, Germany, ⁶Internal Medicine I, University Medical Center of Regensburg, Regensburg, Germany, ⁷Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ⁸Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ⁹Rheumatology Internal Medicine D, University Hospital Münster, Münster, Germany, ¹⁰Internal Medicine II, Hospital Südstadt, Rostock, Germany, ¹¹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹²Rheumaeinheit, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ¹³Division of Rheumatology, University of Munich, Munich, Germany, ¹⁴Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Background/Purpose: Autoimmune diseases are characterized by high morbidity and lead frequently to physical disability and loss of income. They are the third most important disease…
Abstract Number: 1446 • 2013 ACR/ARHP Annual Meeting
The Efficacy Of Etanercept In Combination With Methotrexate In Moderate To Severe Rheumatoid Arthritis Is Not Dependent On The Dosage Of Methotrexate
T.W.J. Huizinga¹, Fiona Brock², Urs Kerkmann³ and Gaia Gallo³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Quanticate, Hitchin, Hertfordshire, United Kingdom, ³Pfizer Europe, Rome, Italy
Background/Purpose: Anti-TNF therapy in combination with a synthetic DMARD such as methotrexate (MTX) has been extensively shown to be superior to MTX and anti-TNF therapy…
Abstract Number: 493 • 2013 ACR/ARHP Annual Meeting
A Real-World Risk Analysis Of Biological Treatment (Adalimumab and Etanercep) In Country With High Prevalence Of Tuberculosis and Hepatitis B/C
Ying-Ming Chiu¹, Chao-Hsiung Tang², Sheng-Tzu Hung³, Ya-Wen Yang⁴, Chi-Hui Fang⁴ and Hsiao-Yi Lin⁵, ¹Changhua Christian Hospital, Changhua City, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³Formosa Biomedical Technology Corp., Taipei, Taiwan, ⁴Pfizer Limited, Taipei, Taiwan, ⁵Immunology and Rheumatology, Dept of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background/Purpose: Biologics have been widely utilized in many rheumatic diseases. Risks associated with the use of biological treatments are revealed in many published studies. Nevertheless,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].